ストックスクリーナーアプリを入手
13.33
0.15%
0.02
アフターアワーズ：
13.20
-0.13
-0.98%
前日終値:
$13.31
開ける：
$13.12
24時間の取引高:
374.16K
Relative Volume:
0.79
時価総額：
$125.53M
収益：
-
当期純損益:
$-81.17M
株価収益率:
-1.3153
EPS:
-10.1344
ネットキャッシュフロー:
$-82.84M
1週間 パフォーマンス:
+24.23%
1か月 パフォーマンス:
+68.73%
6か月 パフォーマンス:
-18.02%
1年 パフォーマンス:
-61.00%
1日の値動き範囲:
$12.87
$13.88
1週間の範囲:
$9.88
$14.94
52週間の値動き範囲:
$5.2044
$55.89
Korro Bio Inc Stock (KRRO) Company Profile
KRRO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KRRO
Korro Bio Inc
|
13.33 | 125.34M | 0 | -81.17M | -82.84M | -10.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.90 | 120.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.45 | 78.77B | 14.34B | 4.50B | 3.88B | 41.57 |
|
ARGX
Argen X Se Adr
|
840.50 | 52.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
338.06 | 45.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
340.38 | 38.73B | 4.98B | 69.59M | 525.67M | 0.5197 |
Korro Bio Inc Stock (KRRO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-29 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2026-01-29 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2026-01-29 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2026-01-28 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2026-01-28 | アップグレード | Oppenheimer | Perform → Outperform |
| 2025-11-13 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2025-11-13 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2025-11-13 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-11-13 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2025-11-13 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-11-13 | ダウングレード | Raymond James | Strong Buy → Mkt Perform |
| 2025-11-13 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2025-04-29 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-04-16 | 開始されました | Chardan Capital Markets | Buy |
| 2025-01-10 | 開始されました | Oppenheimer | Outperform |
| 2024-10-21 | 開始されました | Raymond James | Strong Buy |
| 2024-08-14 | 開始されました | William Blair | Outperform |
| 2024-03-28 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-02-27 | 開始されました | BMO Capital Markets | Outperform |
| 2023-12-04 | 開始されました | H.C. Wainwright | Buy |
| 2023-11-29 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-11-10 | 開始されました | Piper Sandler | Overweight |
| 2023-02-15 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2023-02-13 | ダウングレード | Cowen | Outperform → Market Perform |
| 2021-09-22 | ダウングレード | Goldman | Buy → Neutral |
| 2021-01-27 | アップグレード | JP Morgan | Neutral → Overweight |
| 2020-12-22 | 開始されました | B. Riley Securities | Buy |
| 2020-07-14 | 開始されました | Oppenheimer | Outperform |
| 2020-05-18 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-10-28 | 開始されました | Cowen | Outperform |
| 2019-10-28 | 開始されました | Goldman | Buy |
| 2019-10-28 | 開始されました | JP Morgan | Overweight |
すべてを表示
Korro Bio Inc (KRRO) 最新ニュース
Strength Seen in Korro Bio, Inc. (KRRO): Can Its 13.9% Jump Turn into More Strength? - Nasdaq
Chardan Capital upgrades Korro Bio stock to Buy on KRRO-121 potential By Investing.com - Investing.com Nigeria
Korro Bio's KRRO-121 Receives Strong Analyst Upgrades - Intellectia AI
Korro Bio Shares Rise After Piper Sandler, HC Wainwright Upgrades - marketscreener.com
Korro Bio stock rating upgraded by H.C. Wainwright to Buy on new drug potential - Investing.com
HC Wainwright Upgrades Korro Bio to Buy From Neutral, Price Target is $20 - marketscreener.com
This Fortinet Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Benzinga
HC Wainwright & Co. Upgrades Korro Bio (KRRO) - Nasdaq
KRRO Shares Jump 13% On Analyst UpgradesWhat's Driving The Optimism? - Mena FN
Piper Sandler upgrades Korro Bio stock rating to Overweight on UCD treatment - Investing.com
Chardan Capital upgrades Korro Bio stock to Buy on KRRO-121 potential - Investing.com
Oppenheimer Upgrades Korro Bio (KRRO) - Nasdaq
Korro Bio Shares Rise After Oppenheimer Upgrade - marketscreener.com
Cantor Fitzgerald Upgrades Korro Bio to Overweight From Neutral - marketscreener.com
William Blair reiterates Market Perform rating on Korro Bio stock By Investing.com - Investing.com Canada
Raymond James reiterates Market Perform rating on Korro Bio stock By Investing.com - Investing.com Nigeria
Raymond James reiterates Market Perform rating on Korro Bio stock - Investing.com
Cantor Fitzgerald upgrades Korro Bio stock to Overweight on UCD program - Investing.com
Korro Bio stock holds steady as Jones Trading reiterates Hold rating - Investing.com
Clear Street raises Korro Bio stock price target to $10 on new lead program - Investing.com
Korro Bio Showcases KRRO-121 RNA Editing Program Progress - TipRanks
Korro Bio, Inc. Unveils KRRO-121 as a Potential First-in-Class Treatment - TradingView
Investor Mood: Does Red Rock Resorts Inc have strong fundamentalsJuly 2025 Patterns & Reliable Intraday Trade Alerts - baoquankhu1.vn
Moving Averages: Will Korro Bio Inc benefit from green energy policiesMarket Sentiment Summary & Low Risk High Win Rate Picks - baoquankhu1.vn
Growth Recap: Should I buy Korro Bio Inc stock now2025 Volume Leaders & Safe Capital Growth Stock Tips - baoquankhu1.vn
Korro to Host Virtual Analyst Day on January 27, 2026 - The Manila Times
Parent and liver doctor join Korro Bio to explain ammonia-driven diseases - Stock Titan
FOMO Trade: Should you avoid Korro Bio Inc stock right nowJuly 2025 Price Swings & Verified Momentum Stock Ideas - baoquankhu1.vn
Aug Mood: Is Korro Bio Inc stock a buy or sellPortfolio Gains Report & AI Powered Market Entry Strategies - baoquankhu1.vn
Korro Bio Updates Pipeline, Terminates KRRO-110 REWRITE Trial - TipRanks
Press Release Service: Flashpoint Therapeutics Appoints Venkat R. Krishnamurthy, Ph.D. as Chief Scientific Officer - CRISPR Medicine News
Aug Shorts: Is Advantage Solutions Inc backed by strong institutional buyingMarket Sentiment Review & AI Driven Stock Price Forecasts - baoquankhu1.vn
Korro Bio, Inc. (NASDAQ:KRRO) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Portfolio Shifts: Is Korro Bio Inc. stock positioned for digital transformationTrade Volume Report & Free Long-Term Investment Growth Plans - Bộ Nội Vụ
Korro Bio (NASDAQ:KRRO) Shares Down 5.9% – Here’s What Happened - Defense World
Korro Bio CFO takes medical leave, interim officers appointed - MSN
Will Korro Bio Inc. stock see insider buying2025 Bull vs Bear & Real-Time Price Movement Reports - ulpravda.ru
Inflation Data: Can Korro Bio Inc. stock outperform in 2025 bull marketTrade Analysis Report & Daily Market Momentum Tracking - Улправда
Can Korro Bio Inc. stock outperform in 2025 bull marketWeekly Gains Summary & Long-Term Safe Investment Ideas - Улправда
Market Recap: Can Korro Bio Inc. stock resist market sell offsQuarterly Portfolio Summary & Consistent Profit Alerts - ulpravda.ru
Korro Bio (KRRO) price target decreased by 30.77% to 45.90 - MSN
Is Korro Bio Inc. stock gaining market shareQuarterly Profit Report & Free Community Consensus Stock Picks - Улправда
Will Korro Bio Inc. stock keep outperforming rivalsJuly 2025 Rallies & Free Fast Entry Momentum Trade Alerts - ulpravda.ru
Korro to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Korro to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewswire Inc.
Aug Analyst Calls: Will Korro Bio Inc stock see insider buyingWeekly Market Outlook & Entry and Exit Point Strategies - Bộ Nội Vụ
Korro Bio enhances executive compensation and retention incentives - MSN
User | times-online.comKorro Bio, Inc.Common Stock (Nasdaq:KRRO) Stock Quote - FinancialContent
Korro Bio, Inc. (NASDAQ:KRRO) Receives Average Rating of “Hold” from Analysts - Defense World
Can Korro Bio Stock Hold Up When Markets Turn? - Trefis
Why analysts remain bullish on Korro Bio Inc. stockIPO Watch & Free Low Drawdown Momentum Trade Ideas - Улправда
Korro Bio Inc (KRRO) 財務データ
収益
当期純利益
現金流量
EPS
1.27%
大文字化:
|
ボリューム (24 時間):